Overview
Plain-language guide
Designed for research into Obesity, Weight management research, Body-composition research. It remains investigational for these uses.
It combines three hormone signals involved in fullness, blood-sugar control and energy use. Researchers study whether that combination changes weight and metabolism.
Clinical mechanism
Groups investigational peptides that combine GLP-1 with GIP, glucagon, amylin or other metabolic signaling.
Applications
Human evidence
Early or mid-stage human data exist, but confirmation, replication or long-term follow-up remains incomplete.
Tier 2Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Muscle & recovery profile
Each signal is scored independently from 0–5. There is no composite “best” score.
Evidence classes
What has been studied
- Trials study weight change; body-composition substudies help assess how much lean mass changes alongside fat mass.
What is not established
- These programs are not muscle-growth therapies, and weight loss does not guarantee muscle preservation.
Studied populations
- Adults with obesity or metabolic disease in clinical trials
Major limitations
- Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
- Findings from one population, formulation or indication should not be generalized to another.
Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.
Regulatory status
Investigational. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Known but Manageable Risks
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Multiple developers · Class watchlist. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- Long-term outcomes and real-world safety are not yet established.
- Current phase and catalysts require primary-source confirmation.
Last reviewed
August 5, 2026 · Draft